亚太药业(002370) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was CNY 319,164,772.95, representing a 29.48% increase compared to CNY 246,492,170.82 in the same period last year[7]. - Net profit attributable to shareholders was CNY 65,492,888.74, up 40.05% from CNY 46,764,741.57 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was CNY 64,972,171.00, reflecting a 38.85% increase from CNY 46,793,986.08 in the previous year[7]. - The basic earnings per share increased to CNY 0.12, a rise of 33.33% from CNY 0.09 in the same quarter last year[7]. - The net profit attributable to shareholders for the first half of 2018 is expected to increase by 25.00% to 40.00%, ranging from CNY 12,700.91 million to CNY 14,225.02 million[18]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,970,623,123.08, an increase of 8.49% from CNY 2,738,063,462.43 at the end of the previous year[7]. - The net assets attributable to shareholders reached CNY 2,424,430,556.65, which is a 2.77% increase from CNY 2,359,015,565.31 at the end of the last year[7]. - Short-term borrowings decreased by 62.50% compared to the beginning of the period, mainly due to a reduction in bank borrowings by subsidiaries[14]. Cash Flow - The net cash flow from operating activities was negative at CNY -43,517,271.69, a significant decrease of 170.69% compared to CNY 61,564,589.85 in the same period last year[7]. - Operating cash flow decreased by 170.69% year-on-year, mainly due to increased cash payments for goods and services[15]. Shareholder Information - The company reported a total of 7,521 common shareholders at the end of the reporting period[10]. - Zhejiang Apac Group Co., Ltd. held the largest share with 26.77%, amounting to 143,600,000 shares[10]. Expenditures and Investments - Prepayments increased by 97.77% compared to the beginning of the period, mainly due to increased prepayment for technical services by subsidiaries[14]. - Other current assets increased by 48.00% compared to the beginning of the period, primarily due to an increase in unrecoverable input tax by subsidiaries[14]. - Development expenditures increased by 1608.27% compared to the beginning of the period, mainly due to the purchase of a new drug, recombinant human keratinocyte growth factor-2[14]. - Sales expenses increased by 143.36% year-on-year, primarily due to enhanced market investment and promotion of key products[15]. Return on Investment - The weighted average return on net assets was 2.74%, up from 2.12% in the previous year[7].